Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
10.3971/j.issn.1000-8578.2022.22.0429
- VernacularTitle:免疫检查点抑制剂治疗结直肠癌的疗效及肠道菌群对其疗效影响的研究进展
- Author:
Yijie WANG
1
;
Gangwei ZHANG
;
Chao XU
;
Qinghua YAO
Author Information
1. Second Clinical College, Zhejiang Chinese Medical University, Hangzhou 310053, China
- Publication Type:Research Article
- Keywords:
Colorectal cancer;
Immune checkpoint inhibitors;
Gut microbiome;
Curative effect
- From:
Cancer Research on Prevention and Treatment
2022;49(11):1184-1189
- CountryChina
- Language:Chinese
-
Abstract:
With the rapid development of immunotherapy, an increasing number of immune checkpoint inhibitors have been used in clinical settings. Immunotherapy provides a new treatment option for patients with advanced colorectal cancer metastasis. Studies have confirmed that patients with metastatic colorectal cancer with dMMR/MSI-H status are more sensitive to immunotherapy and have a more objective and sustained clinical response than their counterparts. Gut microbiome has been proved to play a certain regulatory role in tumor immunotherapy response, and some bacteria can affect the efficacy of immune checkpoint inhibitors through the immune system or metabolic function of the body. With the progress of the study, the gut microbiome is expected to become not only the predictive biomarkers of curative effect of colorectal cancer immunotherapy, but it can also be a key regulatory factor influencing the results of colorectal cancer immunotherapy. For future clinical treatment, the use of immune checkpoint inhibitors may benefit patients with advanced colorectal cancer.
